Recordati : Recordati inspires confidence
>Profitability more solid than expected in Q3 - Recordati yesterday evening reported its Q3 2023 figures. Sales came to € 512m (+1% vs consensus), up 5.5% y-o-y despite a negative forex impact of € 29.6m over the period (-€ 59.6m for the first 9 months; -4.6%), driven by the Specialty & Primary Care business (over 10% growth in Q3 excluding the forex impact) and Rare Diseases (+23. 5% since the start of the year), with the endocrinology and oncology franchises growing...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.